WASHINGTON (dpa-AFX) - Arrowhead Research Corp. (ARWR) said it has acquired RNA therapeutics assets from Roche (RHHBY.PK) including the research site in Madison.
The Roche assets and IP acquired by Arrowhead include Roche Madison Inc., license from Tekmira Pharmaceuticals Corp. for proprietary SNALP RNAi delivery; proprietary Liposomal Nanoparticle RNAi delivery system developed by Roche.
The Roche assets and IP acquired by Arrowhead also include license from Alnylam providing access to Alnylam's RNAi IP and Canonical siRNA structures; license from City of Hope providing access to Dicer substrate siRNA structures; license from MDRNA providing access to Meroduplex siRNA structures and a team of over 40 leading scientists in the RNAi field and state-of-the-art facilities and infrastructure in Madison.
As per the terms of the deal, Roche transferred to Arrowhead all of its existing RNAi operations and research facilities in Madison, Wisconsin along with its employees, equipment, related technology licenses and intellectual property covering current and planned development programs. Roche obtained a minority stake in Arrowhead as well as rights to negotiate for certain future products, milestone payments and royalties on sales.
Copyright RTT News/dpa-AFX
© 2011 AFX News
